Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Karyopharm Therapeutics (KPTIQ) Stock Price & Analysis

1,272 Followers

KPTIQ Stock Chart & Stats

$0.02$0.00(0.00%)
At close: 4:00 PM EST
$0$1$2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.01 - $0.02
52-Week Range
$0.01 - $10.99
Previous Close
$0.02
Volume
N/A
Average Volume (3M)
16.60M
Market Cap
$394.66K
Enterprise Value
$473.81M
Total Cash (Recent Filing)
$65.11M
Total Debt (Recent Filing)
$215.88M
Price to Earnings (P/E)
0.0
Beta
2.45
Next Earnings
Feb 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Myelofibrosis Clinical And Regulatory Progress

The SENTRY results and constructive FDA interactions support a potentially meaningful expansion of XPOVIO into myelofibrosis. An on-track regulatory pathway, supported by efficacy and survival signals, could broaden the product’s addressable market and strengthen the company’s long-term commercial platform if confirmatory requirements are met.

Established Commercial Platform

Existing XPOVIO sales provide a commercial foundation while the company advances its myelofibrosis opportunity. Stable U.S. product revenue, an experienced hematology platform, patient support infrastructure, and reaffirmed guidance can support launch readiness and partner economics over the coming quarters.

High Gross Margin And Cost Prioritization

The product’s very high gross margin indicates that incremental revenue could carry substantial contribution potential once operating spending is better aligned with sales. Recent reductions in R&D and SG&A also show prioritization of key programs, which may improve operating leverage if commercial growth materializes.

Bears Say

Chapter 11 Restructuring And Equity Impairment

Chapter 11 places the business under court supervision and creates a major structural overhang for shareholders, with the proposed plan providing no distribution to existing equity. The sale and restructuring process may also change ownership, control, financing terms, and strategic priorities over the next several months.

Stressed Capital Structure And Cash Burn

Negative equity, meaningful debt, and continuing free-cash-flow consumption materially reduce financial flexibility. The company is not self-funding operations and must manage creditor obligations while financing development and commercialization, increasing the risk that future resources are directed toward restructuring rather than growth.

Pipeline Setback And Approval Uncertainty

The failed endometrial cancer endpoint reduces pipeline diversification and concentrates strategic importance on myelofibrosis. Even if accelerated approval is granted, mature overall-survival confirmation is required, leaving timing, label durability, and the ultimate commercial value exposed to execution and regulatory risk.

KPTIQ FAQ

What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $0.01 and its highest was $10.99 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $394.66K.
When is Karyopharm Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 22,681,460 shares outstanding.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Hedge funds hold Karyopharm Therapeutics shares: the largest hedge-fund position in Karyopharm Therapeutics is 70,145,361 shares, and hedge funds increased their holdings by 1.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology